BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ukai K, Ishigami M, Yoshioka K, Kawabe N, Katano Y, Hayashi K, Honda T, Yano M, Goto H. Mutations in carboxy-terminal part of E2 including PKR/eIF2α phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: Their correlation with response to interferon monotherapy and viral load. World J Gastroenterol 2006; 12(23): 3722-3728 [PMID: 16773689 DOI: 10.3748/wjg.v12.i23.3722]
URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3722.htm
Number Citing Articles
1
Scott A. Read, Mark W. Douglas. Advanced Therapy for Hepatitis C2011; : 12 doi: 10.1002/9781444346343.ch2
2
Federico Bolcic, Natalia Laufer, Carolina Torres, Lucila Cassino, Rita Reynoso, Jorge Quarleri. Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patientsAntiviral Research 2012; 95(2): 72 doi: 10.1016/j.antiviral.2012.05.015
3
Alexander Tarr, Tanvi Khera, Kathrin Hueging, Julie Sheldon, Eike Steinmann, Thomas Pietschmann, Richard Brown. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignViruses 2015; 7(7): 3995 doi: 10.3390/v7072809
4
M. F. Derbala, N. Z. El Dweik, S. R. Al Kaabi, A. D. Al‐Marri, F. Pasic, A. B. Bener, F. M. Shebl, A. M. Amer, M. T. Butt, R. Yakoob, A. John, M. Al Mohanadi, M. A. Al Khinji. Viral kinetic of HCV genotype‐4 during pegylated interferon alpha 2a: ribavirin therapyJournal of Viral Hepatitis 2008; 15(8): 591 doi: 10.1111/j.1365-2893.2008.00988.x
5
Johannes G. Bode, Erwin D. Brenndörfer, Dieter Häussinger. Subversion of innate host antiviral strategies by the hepatitis C virusArchives of Biochemistry and Biophysics 2007; 462(2): 254 doi: 10.1016/j.abb.2007.03.033
6
Saba Khaliq, Noreen Latief, Shah Jahan. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatmentArchives of Virology 2014; 159(1): 1 doi: 10.1007/s00705-013-1780-x
7
Kattareeya Kumthip, Niwat Maneekarn. The role of HCV proteins on treatment outcomesVirology Journal 2015; 12(1) doi: 10.1186/s12985-015-0450-x
8
Iman Rad, Maryam Honardoost. Structural Modification in Hepatitis C Virus Envelope Protein; Potential Viral Strategy Against Interferon TherapyInternational Journal of Peptide Research and Therapeutics 2020; 26(1): 171 doi: 10.1007/s10989-019-09826-2
9
Yanli Zeng, Wei Li, Jingtao Li, Junjie Wang, Bin Zhou, Jian Zhang, Shuwen Liu, Yingsong Wu, Jinlin Hou, Yuanping Zhou. Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis CArchives of Virology 2012; 157(6): 1113 doi: 10.1007/s00705-012-1283-1
10
Alicia Amadoz, Fernando Gonzáez-Candelas. A Novel Approach to Identify Candidate Prognostic Factors for Hepatitis C Treatment Response Integrating Clinical and Viral Genetic DataEvolutionary Bioinformatics 2015; 11: EBO.S20853 doi: 10.4137/EBO.S20853
11
Fernanda de Mello Malta, José Eymard Moraes de Medeiros-Filho, Raymundo Soares de Azevedo, Luzia Gonçalves, Luiz Caetano da Silva, Flair José Carrilho, João Renato Rebello Pinho. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitisMemórias do Instituto Oswaldo Cruz 2010; 105(1): 92 doi: 10.1590/S0074-02762010000100014
12
Ijaz Ali, Sanaullah Khan, Sobia Attaullah, Shahid Niaz Khan, Jabbar Khan, Sami Siraj, Aqib Iqbal, Zahoor A Swati, Muhammad Idrees. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A proteinVirology Journal 2011; 8(1) doi: 10.1186/1743-422X-8-258
13
P. Muñoz de Rueda, J. Casado, R. Patón, D. Quintero, A. Palacios, A. Gila, R. Quiles, J. León, A. Ruiz-Extremera, J. Salmerón. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of Hepatitis C Virus Genotype 1 and Their Relationships to Pegylated Interferon-Ribavirin Treatment ResponsesJournal of Virology 2008; 82(13): 6644 doi: 10.1128/JVI.02231-07
14
Shouichi Yokozaki, Yoshiaki Katano, Kazuhiko Hayashi, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Isao Nakano, Hidemi Goto. Mutations in two PKR‐binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsivenessJournal of Medical Virology 2011; 83(10): 1727 doi: 10.1002/jmv.21959
15
Kazuaki Chayama, C Nelson Hayes. Hepatitis C virus: How genetic variability affects pathobiology of diseaseJournal of Gastroenterology and Hepatology 2011; 26(s1): 83 doi: 10.1111/j.1440-1746.2010.06550.x
16
F. Bolcic, M. Sede, F. Moretti, G. Westergaard, M. Vazquez, N. Laufer, J. Quarleri. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatmentArchives of Virology 2012; 157(4): 703 doi: 10.1007/s00705-012-1230-1